# SterileGMP Knowledge Hub — Comprehensive Scope & Roadmap

This document summarizes the current coverage status, gap analysis, and expansion roadmap for building a comprehensive sterile pharmaceutical manufacturing knowledge hub suitable for COO-level operational decision-making.

Last updated: 2026-04-01 (ICH Q trilogy complete: Q8R2 + Q9R1 + Q10; ISPE Vol.6 complete; FDA Aseptic 2004 complete)

---

## Current Status Summary

### PDA Technical Reports & Points to Consider

| Status | Count | Details |
|--------|-------|---------|
| Complete | 33 | All sections generated, merged, verified |
| Skeleton (metadata only) | 0 | — |
| **Total in reports.json** | **33** | |

**Completion: 100%** (PDA phase complete)

### ISPE Guidelines

| Status | Count | Details |
|--------|-------|---------|
| Complete | 8 | Vol.3, Vol.4, Vol.5, Vol.6, HVAC, Vol.7, SUT, GAMP 5 (2nd Ed.) |
| Not yet started | 7 | GEP, CTC, TechTransfer, Sampling, ProcessGas, QualityCulture, IT |
| **Total** | **~15** | |

**Completion: 53%** (see `ISPE/ISPE-PROCESSING-ORDER.md` for prioritized queue)

### Other Sources

| Source | Status |
|--------|--------|
| PIC/S Annex 1 | ✅ Complete |
| FDA Guidances | Aseptic Processing 2004 ✅ |
| ICH Guidelines | Q8(R2) ✅ Q9(R1) ✅ Q10 ✅ — all three complete |
| USP Chapters | Not started |
| ISO Standards | Not started |

**Overall: 49 of ~65-70 target documents complete (approx. 73%)**

---

## Source Organizations in Scope

| # | Source | Scope | Color |
|---|--------|-------|-------|
| 1 | **PDA** | Technical Reports, Points to Consider, Guides | Blue |
| 2 | **ISPE** | Baseline Guides, Good Practice Guides, GAMP | Green |
| 3 | **PIC/S** | Annex 1 (2022) — Manufacture of Sterile Medicinal Products | Orange |
| 4 | **FDA** | Selected Guidance for Industry documents (sterile-relevant only) | Red |
| 5 | **ICH** | Q8(R2), Q9(R1), Q10 only (the "quality trinity") | Purple |
| 6 | **USP** | Selected General Chapters (sterility, endotoxin, particulates, microbial) | Gold |
| 7 | **ISO** | 14644 series (cleanrooms), 17665 (steam sterilization) | Purple |

> **ICH scope note:** Only Q8/Q9/Q10 belong in this hub. The full ICH guideline set (Q1-Q14, S-series, E-series, M-series) covers all pharmaceutical manufacturing and is not sterile-specific. A separate "Pharmaceutical Regulatory Knowledge Hub" would be the appropriate home for the complete ICH library.

---

## Coverage by Domain

### Well Covered (strong existing content)

| Domain | Key Documents | Assessment |
|--------|--------------|------------|
| Aseptic Processing | TR22, TR62, PtC-1, PtC-12, PtC-Isolators, Guide No.1 | Excellent |
| Environmental Monitoring | TR13, TR13-2, TR88 | Excellent |
| Contamination Control (CCS) | TR90, TR70 | Excellent |
| Container/Closure & Packaging | TR73, TR73-2, TR85, TR87, TR43 | Excellent |
| Sterilizing Filtration | TR26 | Good |
| Process Validation | TR60 | Good |
| Single-Use Systems | TR66 | Good |
| Supply Chain & GDP | TR39, TR46, TR52, TR68 | Good (over-represented) |
| Facility Design | ISPE Vol.3, PtC-14 | Good |
| C&Q / Qualification | ISPE Vol.5 | Good |
| ATMP / Cell & Gene Therapy | PtC-13, PtC-14 | Good |
| Data Integrity | TR84 | Covered |
| Regulatory / Change Control | TR91, TR73-2 | Covered |
| Technology Transfer | TR65 | Good |

### Critical Gaps

| Gap | Why It Matters | Recommended Source |
|-----|---------------|-------------------|
| **Regulatory anchor (EU/PIC/S)** | Annex 1 is THE document inspectors cite globally; referenced by nearly every PDA TR in the hub | **PIC/S Annex 1 (2022)** |
| **Regulatory anchor (US)** | FDA equivalent; basis for 483 observations in sterile manufacturing | **FDA Aseptic Processing Guidance (2004)** |
| **Quality Risk Management framework** | Cited by TR90, TR22, TR60, ISPE Vol.5, ISPE Vol.7 — the methodology foundation | **ICH Q9(R1)** |
| **Pharmaceutical Quality System** | The PQS framework that TR91, TR84, TR60 sit inside | **ICH Q10** |
| **Pharmaceutical Development** | Design space / QbD foundation for TR60, TR26 | **ICH Q8(R2)** |
| **Water & Steam Systems** | #1 cause of batch loss and plant shutdowns; zero coverage currently | **ISPE Vol.4** |
| **HVAC** | Every cleanroom depends on this; capital investment decisions | **ISPE HVAC** |
| **Sterility Testing** | The fundamental release test for sterile products | **USP \<71\>** |
| **Endotoxin / Pyrogen Testing** | Endotoxin excursions halt production lines | **USP \<85\>** |
| **Particulate Matter** | Injectable release requirement | **USP \<788\>** |
| **Microbial Control of Aseptic Environments** | EM program design standard | **USP \<1116\>** |
| **Sterilization & Sterility Assurance** | Foundation for all sterilization methods | **USP \<1211\>** |
| **Lyophilization** | Major sterile dosage form, completely absent | **PDA TR36** |
| **Container Closure Integrity (CCI)** | Dedicated CCI testing methodology missing | **PDA TR27** |
| **Cleanroom Standards** | Referenced by every facility document | **ISO 14644-1/2/3** |

### COO-Specific Knowledge Gaps

Beyond guidelines, a COO needs decision-oriented, synthesized knowledge:

| Gap | Description |
|-----|------------|
| **Inspection readiness** | Common FDA 483 observations for sterile facilities (publicly available from FDA database) |
| **Deviation / CAPA management** | Triage frameworks, investigation resource allocation, CAPA timelines |
| **Batch disposition decision-making** | When to release, reject, or reprocess — risk-based decision trees |
| **Operational metrics** | OEE, batch success rate, right-first-time, cycle time benchmarks |
| **Quality culture** | ISPE-PDA Quality Culture guide (scaffolded, not yet built) |

---

## Phased Expansion Roadmap

### Phase 1: Complete Current Sources (PDA 100% + Top ISPE)

**Goal:** Finish what's started before adding new source organizations.

| Task | Document | Effort |
|------|----------|--------|
| ~~Complete PDA skeleton~~ | ~~TR41: Virus Retentive Filtration~~ | ✅ Done |
| ~~Complete PDA skeleton~~ | ~~TR54: Formalized Risk Assessment for Excipients~~ | ✅ Done |
| ~~Complete PDA skeleton~~ | ~~TR56: Phase-Appropriate Quality Systems for Biologics~~ | ✅ Done |
| ~~Complete PDA skeleton~~ | ~~TR62: Manual Aseptic Processes~~ | ✅ Done |
| ~~Process ISPE #3~~ | ~~ISPE HVAC~~ | ✅ Done |
| ~~Process ISPE #4~~ | ~~ISPE Vol.4: Water & Steam Systems~~ | ✅ Done |
| ~~Process ISPE #5~~ | ~~ISPE Vol.7: Risk-Based Manufacture~~ | ✅ Done |
| ~~Process ISPE #6~~ | ~~ISPE SUT: Single-Use Technology~~ | ✅ Done |
| ~~Process ISPE #7~~ | ~~ISPE GAMP 5~~ | ✅ Done |

**Phase 1 complete.** Next: Phase 2 (PIC/S Annex 1 → FDA → ICH).

### Phase 2: Regulatory Anchors + ICH Foundation

**Goal:** Add the regulatory backbone that every existing document references.

| Task | Document | Effort |
|------|----------|--------|
| ~~**New source: PIC/S**~~ | ~~PIC/S Annex 1 (2022)~~ | ✅ Done |
| ~~**New source: FDA**~~ | ~~Aseptic Processing Guidance (2004)~~ | ✅ Done |
| **New source: FDA** | Process Validation Guidance (2011, Rev 2) | Medium |
| **New source: FDA** | Process Inspection Guidance | Medium |
| ~~**New source: ICH**~~ | ~~Q9(R1) Quality Risk Management~~ | ✅ Done |
| ~~**New source: ICH**~~ | ~~Q10 Pharmaceutical Quality System~~ | ✅ Done |
| ~~**New source: ICH**~~ | ~~Q8(R2) Pharmaceutical Development~~ | ✅ Done |

### Phase 3: Pharmacopeial Standards + Cleanrooms

**Goal:** Add the test methods and standards that define "how you measure compliance."

| Task | Document | Effort |
|------|----------|--------|
| **New source: USP** | \<71\> Sterility Tests | Small |
| **New source: USP** | \<85\> Bacterial Endotoxins Test | Small |
| **New source: USP** | \<788\> Particulate Matter in Injections | Small |
| **New source: USP** | \<1116\> Microbial Control of Aseptic Environments | Small |
| **New source: USP** | \<1211\> Sterilization and Sterility Assurance | Medium |
| **New source: ISO** | ISO 14644-1/2/3 (Cleanroom classification) | Medium |

### Phase 4: Topic Gap-Fillers + Remaining ISPE

**Goal:** Fill remaining content gaps and complete the ISPE library.

| Task | Document | Effort |
|------|----------|--------|
| Fill lyophilization gap | PDA TR36 (or equivalent) | Medium |
| Fill CCI gap | PDA TR27 (Package Integrity) | Medium |
| Fill steam sterilization gap | ISO 17665 | Medium |
| Complete ISPE #9-15 | GEP, CTC, TechTransfer, Sampling, ProcessGas, QualityCulture, IT | Large (cumulative) |
| Additional FDA | Container Closure Guidance, Terminal Sterilization Guidance | Medium |
| Additional USP | \<787\>, \<790\>, \<1228\>, \<1229\>, \<382\>, \<661\> | Medium (cumulative) |

### Phase 5: COO Decision Support Layer (Future)

**Goal:** Synthesize cross-document knowledge into decision-oriented resources.

| Task | Description |
|------|------------|
| FDA 483 analysis | Common sterile manufacturing observations — cross-referenced to hub documents |
| Deviation triage framework | Synthesized from ICH Q9, Q10, TR88, TR90 |
| Batch disposition decision trees | Risk-based release/reject/reprocess guidance |
| Inspection readiness checklists | Per-area checklists mapped to Annex 1, FDA guidance |
| Operational KPI benchmarks | Industry benchmarks for sterile manufacturing metrics |

---

## Documents NOT in Scope

These are explicitly excluded to keep the hub focused on sterile pharmaceutical manufacturing:

| Document | Why Excluded |
|----------|-------------|
| ICH Q1-Q7, Q11-Q14 | General pharma — not sterile-specific. Belongs in a separate regulatory hub. |
| ICH S-series, E-series, M-series | Safety, efficacy, multidisciplinary — not manufacturing-focused. |
| WHO TRS series | Only relevant if audience includes WHO-prequalified market manufacturers. |
| European Pharmacopoeia (EP) | Largely mirrors USP for sterile methods. Add only if EU-specific chapter numbers are needed. |
| ASTM standards | ASTM E2500 (verification) is influential but too niche for this hub. |
| ISO 11135 (EtO sterilization) | Rarely used for sterile injectables. |
| ISO 11137 (Radiation sterilization) | Niche sterilization method for devices, not primary for pharma injectables. |
| Full PDA TR catalog | Many TRs cover non-sterile topics (oral solids, APIs). Only sterile-relevant TRs are included. |

---

## Folder Structure (Target State)

```
/
├── PDA/                    # PDA Technical Reports, Points to Consider, Guides
│   ├── TR13/
│   ├── TR22/
│   ├── TR26/
│   ├── TR27/               # Future: Container Closure Integrity
│   ├── TR36/               # Future: Lyophilization
│   └── ...
├── ISPE/                   # ISPE Baseline Guides & Good Practice Guides
│   ├── ISPE-Vol3/
│   ├── ISPE-Vol4/
│   ├── ISPE-Vol5/
│   ├── ISPE-HVAC/
│   └── ...
├── PICS/                   # PIC/S (future)
│   └── PICS-Annex1/
├── FDA/                    # FDA Guidance for Industry (scaffolded, content pending)
│   ├── FDA-Aseptic/
│   ├── FDA-ProcessVal/
│   └── FDA-ProcessInspection/
├── ICH/                    # ICH Q8, Q9, Q10 only (future)
│   ├── ICH-Q8R2/
│   ├── ICH-Q9R1/
│   └── ICH-Q10/
├── USP/                    # USP General Chapters (future)
│   ├── USP-71/
│   ├── USP-85/
│   ├── USP-788/
│   ├── USP-1116/
│   └── USP-1211/
├── ISO/                    # ISO Standards (future)
│   └── ISO-14644/
├── knowledge/              # Chatbot knowledge base (English-only)
│   ├── INDEX.md
│   ├── PDA/
│   ├── ISPE/
│   ├── PICS/               # Future
│   ├── FDA/                # Future
│   ├── ICH/                # Future
│   ├── USP/                # Future
│   └── ISO/                # Future
├── reports.json            # Single source of truth
├── index.html              # Dashboard
└── ROADMAP.md              # This file
```

---

## Estimated Target: ~65-70 Documents

| Source | Current | Target | Notes |
|--------|---------|--------|-------|
| PDA | 33 | ~35 | Add TR27, TR36; complete 4 skeletons |
| ISPE | 15 | 15 | Complete all scaffolded guides |
| PIC/S | 1 | 1 | Annex 1 ✅ |
| FDA | 1 | 3-4 | Aseptic Processing ✅, Process Validation, Process Inspection, Container Closure |
| ICH | 3 | 3 | Q8(R2) ✅ Q9(R1) ✅ Q10 ✅ |
| USP | 0 | 5-8 | \<71\>, \<85\>, \<788\>, \<1116\>, \<1211\>, optionally \<787\>, \<790\>, \<1228\> |
| ISO | 0 | 2-3 | 14644-1/2/3, optionally 17665 |
| **Total** | **52 (46 complete)** | **~65-70** | |

The infrastructure (tooling, workflow, dashboard, chatbot) is already built. The remaining work is content processing — the hardest part of the project is done.
